Chief Scientific & Innovation Officer- Orlando Health Cancer Institute. Driving Phase 1–3 trials, biotech partnerships & AI-enabled research 🧬💻
Orlando, FL
Joined April 2012
- Tweets2.9K
- Following310
- Followers874
- Likes9.9K
Pinned Tweet
Excited to share that I’ve joined @OrlandoHealth Cancer Institute as Chief Scientific & Innovation Officer.
Grateful for the incredibly warm welcome from the OHCI team!
Onward and upward
#PatientsFirst #OrlandoHealth #Oncology #ClinicalTrials #Innovation #Biotech #Pharma
7
42
1,675
Jad Chahoud retweeted
1/5 Our latest #MsaouelLab article in @EurUrolOncol introduces RMC-COMPASS, the first prognostic model designed specifically for patients with SMARCB1-deficient #RenalMedullaryCarcinoma: authors.elsevier.com/a/1o3ol… #endRMC #MsaouelLab #rarecancers #kidneycancer
Jad Chahoud retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
💯 @shilpaonc! Beyond his visionary leadership. @montypal is a leader that passes the mirror test! Building the next generation of oncologists takes action. I watched Monty ask that junior faculty who drove trial enrollment take his NEJM authorship spot. He walks the talk @ASCO
Couldn't agree more! @montypal led our @ASCO LDP program 2024-25 and we were fortunate to learn from his incredible insights on hands on leadership!
His visionary leadership is exactly what ASCO needs to expand the global footprint and nurture the next generation of leaders in oncology!
@IbiayiMD @minasedrakmd @NVijayvergiaMD @fumikochino @StephenChunMD @JadChahoud
Jad Chahoud retweeted
1/5 New in @EurUrolOncol: the largest series yet of metastasis-directed radiation therapy in SMARCB1-deficient #RenalMedullaryCarcinoma. Key finding that this cancer appears far more radiosensitive than clear cell kidney cancer: authors.elsevier.com/c/1n~As… #endRMC #MsaouelLab
Jad Chahoud retweeted
(1/4) Here's our clinical lab’s latest work led by @MitchellBoshkos, PGY-3, evaluating how cardiometabolic factors influence response to pre-operative ADT +/- ARPI in localized HRPCa in @pcan_journal
tinyurl.com/3u8r4vf9
Jad Chahoud retweeted
Accrual speed and characteristics of phase III U.S. cancer clinical trials with frequently used biomarkers in eligibility criteria.
asco.org/abstracts-presentat…
@ASCO @CharlesJiangMD
#ASCOQLTY26 #Cancer #ClinicalTrials
Jad Chahoud retweeted
Our thoughts on the recent approval of adjuvant pembro + belzutifan for ccRCC led by outstanding fellow @SM_Esagian in @ASCOPost tinyurl.com/4r3dsvhs @PavlosMsaouel
Jad Chahoud retweeted
To mark Penile Cancer Awareness Day, the GSRGT is proud to officially launch PCARE — our new patient advocacy initiative supporting people affected by #PenileCancer.
If you are a patient or caregiver looking for support or guidance, please contact us at [email protected] 📩
Special thanks to @SpiessPhilippe, @LuisMedinaMD, and @JadChahoud for bringing this initiative to life.
@drgaganprakash @npaesa @CMercinelli @CurtisPettaway1 @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @herneygarcia @PGrivasMDPhD @UroDocAsh @spsutkaMD @montypal @shilpaonc @orchidcancer @karima_oualla @VedangMurthy @UrogerliMD
Jad Chahoud retweeted
1/5 New in @UrolOncol: consensus statements from the IKCS North America 2025 Think Tank on trials for rare kidney cancers. 46 experts. 20 statements. One message: move beyond pooled “non-clear cell” #kidneycancer primary analyses: authors.elsevier.com/a/1nmZc…
Jad Chahoud retweeted
Thank you for everything you do for GU research, for the countless hours you dedicate to reviewing for @EUplatinum and for continuing to push our field forward
🎉 Congratulations to our September Reviewer of the Month, Prof. @JoshMeeks!
Your commitment to the Platinum Journal keeps us a cut above the rest. Thank you!
Jad Chahoud retweeted
1/5 Our study on panitumumab-based EGFR blockade in renal medullary carcinoma (RMC) is out in Clinical Cancer Research: aacrjournals.org/clincancerr… #MsaouelLab, #endRMC #kidneycancer
Jad Chahoud retweeted
Federal and Industry Sponsorship in US #Cancer Clinical Trials.
jamanetwork.com/journals/jam…
@JAMA_current @JAMANetwork @JAMAOnc
#CancerResearch #ClinicalTrials
@DrJoeUnger @DrDawnHershman
Jad Chahoud retweeted
Outstanding Grand Rounds on AML Treatment Strategies with Yale University Expertise - Jad Chahoud
@JadChahoud
oncodaily.com/voices/jad-cha…
Grateful to have hosted Dr @dralainmina @YaleCancer at @orlandohealth Cancer Institute for an outstanding Grand Rounds on redefining cure in AML across the transplant continuum.
Thank you, Alain, for sharing your expertise and spending time with our OHCI team!#Leukemia
🤖 Made with AI
Jad Chahoud retweeted
Thank you to our growing global community for supporting the GSRGT and our mission!
Interested in rare GU tumors? Follow @gtumors and join our growing global community! 🌎
@SpiessPhilippe @drgaganprakash @npaesa @CMercinelli @AmerUrological @UroOnc @SUO_YUO @CAU_URO @JadChahoud @benristau @PGrivasMDPhD @spsutkaMD @CMercinelli @LuisMedinaMD @herneygarcia @AndreaNecchi @apolo_andrea @VedangMurthy @ARRODRIGUEZMD @montypal @UrogerliMD @dramandeeparora @CurtisPettaway1 @karima_oualla
Jad Chahoud retweeted
Sharing a new publication in @UrolOncol exploring key gaps in penile cancer care and where the field is headed—from patient advocacy and organ preservation to optimizing surgical management and emerging systemic therapy options.
Thanks to the entire team @SalvadorjcMD @f_eskenazi_MD @jpdugartemd @JadChahoud @SpiessPhilippe @GTumors
doi.org/10.1016/j.urolonc.20…
Jad Chahoud retweeted
First signal that an off-the-shelf CAR T can work in a solid tumor: allogeneic CD70-targeted ALLO-316 in checkpoint- and TKI-refractory clear cell RCC.
🧪 TRAVERSE phase 1a/b, 51 patients, median 4 prior lines
🎯 ORR 25% in the expansion cohort, 31% if CD70-high (TPS ≥50%)
⚠️ Grade ≥3 CRS 2%, no grade ≥3 ICANS
Not clinic-ready, but this is proof of concept that an allogeneic product can drive responses in refractory RCC, with CD70 as a usable enrichment tool. A real milestone.
Open-access JCO: bit.ly/Srour-TRAVERSE
@montypal @JadChahoud @kotechamd #KidneyCancer #RCC #CARTcell
Jad Chahoud retweeted
10 Must-Read Posts in GU Oncology This Week | Third Week of July
This week’s selection covers:
• PSMA-PET/CT in mCSPC
• Precision medicine in testicular cancer
• ALLO-316 CAR T-cell therapy in advanced ccRCC
• AI biomarkers in metastatic RCC
• Outcomes in metastatic NSGCT
• SBRT ± ADT in elderly patients with aggressive localized prostate cancer
• Enzalutamide in biochemically recurrent prostate cancer
• FGFR3-altered bladder cancer and morphology
• ESTRO focal boost recommendations in prostate radiotherapy
• microRNAs as potential biomarkers in penile cancer
@kimvdvelden @JoaoPedroLobo89 @JadChahoud @RebuzziSara @KNJobanputra @fcounago @nealshore @LiangChengMD @radioncoluis
Read more on OncoDaily - oncodaily.com/genitourinary-…
#GUOncology #OncoDaily
Jad Chahoud retweeted
Really important proof of concept trial in RCC of allogeneic CART cell therapy from @KotechaMD @JadChahoud @montypal #NizarTannir et al.
@MSKCancerCenter @MSK_DeptOfMed @UrologyMSK @JCO_ASCO
Congratulations to @KotechaMD and colleagues on this important @JCO_ASCO publication evaluating allogeneic CD70-directed CAR T-cell therapy in advanced RCC.
🚨 ascopubs.org/doi/10.1200/JCO…
Jad Chahoud retweeted
The patient voice should never be an afterthought.
This inspiring @NatRevUrol article by John Osborne highlights the profound psychological, and social impact of penile cancer—and the critical role of patient advocacy.
“Psychological support for men with penile cancer is not optional: it’s essential”
📄 doi.org/10.1038/s41585-026-0…
@SpiessPhilippe @drgaganprakash @npaesa @CMercinelli @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @orchidcancer @ERN_eUROGEN @EauPatient @JadChahoud
